Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead

Executive Summary

A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.

You may also be interested in...



Pharma Is Ready And Waiting For A Tax Holiday Under Trump

US biopharmas are holding billions in cash overseas to avoid paying America’s high corporate tax rate, so the prospect of a US tax holiday – or broad tax reform – will be welcomed by industry.

Trump’s ACA Repeal: What’s In It For Biopharma?

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Trump’s ACA Repeal: What’s In It For Biopharma?

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel